Jakavi

OTHER2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Polycythemia VeraPost-essential Thrombocythemia MyelofibrosisPost-polycythemia Vera MyelofibrosisPrimary Myelofibrosis

Unknown Phase

A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With Myelofibrosis

CompletedNCT05044026

Novartis PharmaceuticalsPost-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Primary Myelofibrosis

Start: 2012-09-20End: 2022-09-19Updated: 2023-09-21

A Prospective, Non-interventional Study of JAKAVI® (Ruxolitinib) Treatment in Patients With Polycythemia Vera

CompletedNCT05853445

Novartis PharmaceuticalsPolycythemia Vera

Start: 2015-08-17End: 2023-05-03Updated: 2024-05-06

Related Papers

Final Results From a Large, Non‐Interventional, Phase 4 Study of Ruxolitinib for the Treatment of Myelofibrosis in Clinical Routine

European Journal Of Haematology2025-07-06

Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial.

2023-10-048 citations